Online Database of Chemicals from Around the World Search | Submit | Advertise

Home >> Chemical Listing >> Ombitasvir>> Market Analysis Reports
 

Market Analysis Reports of Ombitasvir

Hepatitis C Virus (HCV) - Market Insights, Epidemiology, and Market Forecast - 2030
... (PI). Harvoni (ledipasvir/sofosbuvir), Viekira Pak (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets ... (ledipasvir and sofosbuvir), Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir ...

Hepatitis C: KOL Insight
... ) Viekira Pak/Viekirax+Exviera (paritaprevir/ ombitasvir/ dasabuvir; AbbVie/Enanta) Zepatier (elbasvir ...

Global Hepatitis Drugs Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023
Overview: Hepatitis is a medical condition where the liver is predominantly affected, which can also affect the digestive system and brain. There are three major types of hepatitis condition – HAV, HBV, and HCV. HCV is a major public health problem that ...

NPS+ Hepatitis C Virus (HCV) Infection US [2018]
... ) Sovaldi (sofosbuvir; Gilead) Viekira Pak (ombitasvir/paritaprevir/ritonavir; AbbVie) Zepatier (elbasvir ...

NPS+ Hepatitis C Virus (HCV)Infection (EU5) [2018]
... Cilag) Sovaldi (sofosbuvir; Gilead) Viekirax (ombitasvir/paritaprevir/ritonavir; AbbVie) Zepatier (elbasvir ...

Worldwide - Hepatitis C Drugs Market and Pipeline Drugs Analysis to 2019
... or RG7128 7. Sunvepra (Asunaprevir) 8. ABT-450/r + Ombitasvir (ABT-267) + Dasabuvir (ABT-333 ...

Hepatitis C: Update Bulletin [February 2016]
... KOLs think of AbbVie’s Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged ... concerns about AbbVie’s Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged ...

Physician Views: And then there were two – will AbbVie's 3-DA regimen prove a compelling competitor to Gilead's Harvoni?
... AbbVie's oral '3-DA' product - comprising Viekirax (ombitasvir/ paritaprevir/ ritonavir) plus Exviera (dasabuvir ...




Copyright ©  chemBlink. All rights reserved. Content Disclaimer | about chemBlink | Contact